Tag: Biosciences
Arcus Biosciences expected to rise sharply after the release of Roche cancer data – 08/23/2023 at 15:02
(AOF) – Arcus Biosciences is expected to rise more than 30% before the opening on Wall Street. The American laboratory specializing in combination therapies against cancer has benefited from the…
NFL BIOSCIENCES: STRENGTHENING OF A FOUNDING SHAREHOLDER BY EXERCISE OF BSPCE – 07/05/2023 at 19:01
NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company that develops botanical drugs for the treatment of addictions and dependencies, has been informed of the exercise of…
NFL BIOSCIENCES: Agreement to grant its patent on NFL-101 in Europe and validation of the clinical development plan for NFL-101 by the EMA – 06/21/2023 at 18:15
NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of dependencies and addictions, announces that it has received approval from the…
Merck and co inc: Completed the acquisition of Prometheus Biosciences
Read also (CercleFinance.com) – Merck announced on Friday that it has completed the acquisition of Prometheus Biosciences, this structure now becoming a wholly owned subsidiary of Merck. Under the terms…
NFL BIOSCIENCES: 1st inclusion of a volunteer in the PRECESTO study – 2023-02-22 at 18:00
This Phase IIa clinical study, entitled PRECESTO, was approved by the National Agency for the Safety of Medicines and Health Products (ANSM), and received the favorable opinion of the Committee…
NFL Biosciences collaborates with the CEA – 02/02/2023 at 17:54
NFL-Biosciences will use the CEA’s molecular imaging resources to better understand the mechanism of action of NFL 101. NFL-101 derives from a subcutaneous desensitization treatment which had been developed by…
Very successful capital increase of NFL Biosciences with more than 3 million euros raised – 01/31/2023 at 07:45
Very successful capital increase of NFL Biosciences with more than 3 million euros raised• Strong success of placement with professional investors with a diversified base of French and international investors…
NFL Biosciences: Financial communication agenda for the 1st half of 2023 – 01/17/2023 at 17:45
NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of dependencies and addictions, and in particular NFL-101, its drug candidate for…
Merck: agreement to acquire Imago BioSciences
(CercleFinance.com) – Merck (MSD outside North America) announces that it has entered into a definitive agreement to acquire Imago BioSciences, at a price of 36 dollars per share in cash,…
NFL Biosciences: new patent application
By Jean-Noel Legalland Published on 02/11/2022 at 08:33 Photo credit © ChaunuPictures (Boursier.com)…
NFL Biosciences’ experimental drug to cure tobacco addiction will also be tested in India
NFL Biosciences is a hit on the stock market today. The shares of this biopharma, which is working on a drug intended for smoking cessation, gained nearly 40%, signing the…
Senti Biosciences, Inc.: Positive opinion from Chardan Research
Marketzone with MT Newswires 2022 All the news about SENTI BIOSCIENCES, INC. 09/22 SENTI BIOSCIENCES, INC. : Positive opinion of Chardan Research…